Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion surgery rate remain suboptimal. Irreversible electroporation (IRE) is a non-thermal ablation technique that can induce tumor cell death while preserving surrounding vascular and biliary structures. Emerging evidence suggests that IRE may enhance anti-tumor immunity and synergize with systemic therapy. This prospective, single-center, open-label study aims to evaluate the efficacy and safety of IRE combined with lenvatinib and sintilimab in patients with advanced HCC. Eligible patients with unresectable CNLC stage IIa, IIb, or IIIa disease will receive standard targeted therapy and immunotherapy with or without IRE according to treatment allocation. The primary endpoints are objective response rate (ORR) and conversion surgery rate. Secondary endpoints include time to response (TTR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). The study is expected to provide evidence regarding the role of IRE in enhancing tumor response and increasing the likelihood of curative-intent surgical resection in patients with advanced HCC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Potwierdzony rak wątroby, niemożliwy do chirurgicznego usunięcia
- •Co najmniej jeden widoczny guz do zmierzenia
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Prawidłowa funkcja wątroby (klasa Child-Pugh A lub B)
- •Prawidłowe wyniki badań krwi (liczba płytek, białe krwinki, hemoglobina) i funkcja nerek
- •Możliwość leczenia lekami lenwatynibu i sintilimabu
- •Zdolność do podpisania świadomej zgody
✗ Disqualifies
- •Przerzuty guza poza wątrobę
- •Wcześniejsze leczenie elektroporacją
- •Wcześniejsze leczenie innymi lekami, które uniemożliwia użycie lenwatynibu lub sintilimabu
- •Rozległy guz wątroby niemożliwy do leczenia elektroporacją
- •Niekontrolowane zaburzenia wątroby (płyn w brzuchu, zaburzenia świadomości, krwawienia)
- •Aktywna ciężka infekcja wymagająca leczenia antybiotykami
- •Niekontrolowana białaczka (aktywny wirus zapalenia wątroby B)
- •Ciężkie problemy serca lub ciąża
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Peking Union Medical College Hospital
Beijing, China
Trial contact
Jiayue Li
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.